000			01932 a2200493 4500
005			20250516080846.0
264		0	_c20121226
008			201212s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdr620 _2doi
040			_aNLM _beng _cNLM
100	1		_aCzuczman, M S
245	0	0	_aPhase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cSep 2012
300			_a2356-2362 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunization, Passive
650	0	4	_aInduction Chemotherapy
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLymphoma, Follicular _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aRituximab
650	0	4	_aSeverity of Illness Index
650	0	4	_aTreatment Outcome
650	0	4	_aYoung Adult
700	1		_aLeonard, J P
700	1		_aJung, S
700	1		_aJohnson, J L
700	1		_aHsi, E D
700	1		_aByrd, J C
700	1		_aCheson, B D
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 23 _gno. 9 _gp. 2356-2362
856	4	0	_uhttps://doi.org/10.1093/annonc/mdr620 _zAvailable from publisher's website
999			_c21566794 _d21566794